E. Chen

发表

University of Southern Denmark Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease an international, randomised, double-blind, placebo-controlled trial

Deepak L. Bhatt, Shrikant, P. Commerford, 2018 .

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).

C. Held, P. Armstrong, F. Van de Werf, 2014, The American journal of cardiology.

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).

C. Held, P. Armstrong, F. Van de Werf, 2015, The American journal of cardiology.

Clinical Trial Educator program – a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial

P. Aurup, T. Schwab, Belinda Schegg, 2012, Clinical trials.

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).

Manesh R. Patel, C. Held, P. Armstrong, 2014, American heart journal.

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

Sunil V. Rao, C. Held, P. Armstrong, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

K. Mahaffey, R. Becker, M. Valgimigli, 2014, Thrombosis and Haemostasis.

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).

P. Armstrong, F. Van de Werf, H. White, 2014, The American journal of cardiology.

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial

C. Held, P. Armstrong, F. Van de Werf, 2012, European heart journal. Acute cardiovascular care.

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.

C. Held, P. Armstrong, F. Van de Werf, 2013, European heart journal.

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

C. Held, P. Armstrong, F. Van de Werf, 2014, Journal of the American College of Cardiology.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Giuseppe Ambrosio, Claes Held, Marco Valgimigli, 2012, The New England journal of medicine.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2017, The New England journal of medicine.

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)

Marc P. Bonaca, Sonia S Anand, W. Hiatt, 2018, American heart journal.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2017, The Canadian journal of cardiology.

Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial

Donnell, Eld, Deepak L. Bhatt, 2017 .

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

C. Held, B. Lewis, R. Diaz, 2009, American heart journal.

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.

C. Held, P. Armstrong, F. Van de Werf, 2014, American heart journal.

The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction.

M. Grzybowski, C. Ndumele, L. Parsons, 2004, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

C. Held, P. Armstrong, F. Van de Werf, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

C. Held, K. Alexander, P. Armstrong, 2016, American heart journal.